4P7U

Extracellular domain of type II Transforming Growth Factor Beta receptor in complex with NDSB-201


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.502 Å
  • R-Value Free: 0.206 
  • R-Value Work: 0.171 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

The non-detergent sulfobetaine-201 acts as a pharmacological chaperone to promote folding and crystallization of the type II TGF-beta receptor extracellular domain.

Wangkanont, K.Forest, K.T.Kiessling, L.L.

(2015) Protein Expr.Purif. 115: 19-25

  • DOI: 10.1016/j.pep.2015.06.001

  • PubMed Abstract: 
  • The roles of the extracellular domain of type II TGF-β receptor (TBRII-ECD) in physiological processes ranging from development to cancer to wound healing render it an attractive target for exploration with chemical tools. For such applications, larg ...

    The roles of the extracellular domain of type II TGF-β receptor (TBRII-ECD) in physiological processes ranging from development to cancer to wound healing render it an attractive target for exploration with chemical tools. For such applications, large amounts of active soluble protein are needed, but the yields of TBRII-ECD we obtained with current folding protocols were variable. To expedite the identification of alternative folding conditions, we developed an on-plate screen. This assay indicated that effective folding additives included the non-detergent sulfobetaine-201 (NDSB-201). Although NDSB-201 can facilitate protein folding, the mode by which it does so is poorly understood. We postulated that specific interactions between NDSB-201 and TBRII-ECD might be responsible. Analysis by X-ray crystallography indicates that the TBRII-ECD possesses a binding pocket for NDSB-201. The pyridinium group of the additive stacks with a phenylalanine side chain in the binding site. The ability of NDSB-201 to occupy a pocket on the protein provides a molecular mechanism for the additive's ability to minimize TBRII-ECD aggregation and stabilize the folded state. NDSB-201 also accelerates TBRII-ECD crystallization, suggesting it may serve as a useful crystallization additive for proteins refolded with it. Our results also suggest there is a site on TBRII-ECD that could be targeted by small-molecule modulators.


    Organizational Affiliation

    Department of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, WI 53706, United States. Electronic address: wangkanont@wisc.edu.,Department of Bacteriology, University of Wisconsin-Madison, 1550 Linden Dr., Madison, WI 53706, United States. Electronic address: forest@bact.wisc.edu.,Department of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, WI 53706, United States; Department of Biochemistry, University of Wisconsin-Madison, 433 Babcock Dr., Madison, WI 53706, United States. Electronic address: kiessling@chem.wisc.edu.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
TGF-beta receptor type-2
A
112Homo sapiensMutation(s): 2 
Gene Names: TGFBR2
EC: 2.7.11.30
Find proteins for P37173 (Homo sapiens)
Go to Gene View: TGFBR2
Go to UniProtKB:  P37173
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
1PS
Query on 1PS

Download SDF File 
Download CCD File 
A
3-PYRIDINIUM-1-YLPROPANE-1-SULFONATE
1-(3-SULFOPROPYL) PYRIDINIUM, PPS
C8 H11 N O3 S
REEBJQTUIJTGAL-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.502 Å
  • R-Value Free: 0.206 
  • R-Value Work: 0.171 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 33.574α = 90.00
b = 40.463β = 90.00
c = 75.837γ = 90.00
Software Package:
Software NamePurpose
DENZOdata reduction
PHENIXrefinement
PHASERphasing
SCALEPACKdata scaling
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical SciencesUnited StatesGM055984

Revision History 

  • Version 1.0: 2015-06-24
    Type: Initial release
  • Version 1.1: 2015-09-30
    Type: Database references
  • Version 1.2: 2017-09-13
    Type: Author supporting evidence, Derived calculations, Refinement description